YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Ariad Pharma Cancels Trial

October 21, 2013 | Ariad Pharmaceuticals abruptly terminated a clinical trial for a leukemia drug on Friday, after early trial data from 150 sites suggested safety issues such as blood clots, strokes, and heart attacks. Ariad stock has fallen 84.4% since Friday. However, a spokeswoman for the Leukemia and Lymphoma Society pointed out that the trial did reveal important information. "This is the clinical trial process at work," she said. Boston Globe
Click here to log in.


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 ,